Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 3/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | HPGD | P15428 | 6/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.45 |
| ▸ | GGT1 | P19440 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2746395 | 0.91 | KDM4E (0.57) | KDM4EEPHX2CNR2FAAHCNR1 | |
| SCHEMBL2746617 | 0.78 | KDM4E (0.53) | KDM4EEPHX2CNR2FAAHCNR1 | |
| SCHEMBL14244393 | 0.75 | KDM4E (0.64) | KDM4EEPHX2CNR2FAAHCNR1 | |
| SCHEMBL6859389 | 0.74 | MEN1 (0.39) | KDM4EEPHX2CNR2FAAHCNR1 | |
| SCHEMBL8134445 | 0.73 | CYP19A1 (0.46) | KDM4ECNR2FAAHALDH1A1HPGD | |
| SCHEMBL3927497 | 0.73 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL3793920 | 0.73 | ALDH1A1 (0.41) | KDM4EEPHX2CNR2FAAHALDH1A1 | |
| Phthalic Acid SCHEMBL28793332 | 0.72 | ALDH1A1 (0.70) | KDM4EALDH1A1HPGDHSD17B10HMGB1 | |
| SCHEMBL16793242 | 0.72 | TRPV6 (0.40) | KDM4EEPHX2CNR2FAAHCNR1 | |
| SCHEMBL27890922 | 0.72 | ALDH1A1 (0.46) | KDM4EEPHX2CNR2FAAHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6734208-B2 | ADJUSTMENT TRANSFORMING GROWTH FACTOR CONCENTRATION; ANTIINFLAMMATORY AGENTS | NEORX CORPORATION | 2004-05-11 | — | — | US | claimed |
| US-7511070-B2 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | PONIARD PHARMACEUTICALS, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7084171-B2 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | NEORX CORPORATION (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060084696-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | PONIARD PHARMACEUTICALS, INC. | 2006-04-20 | — | — | US | disclosed |
| US-20050020667-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | PONIARD PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | disclosed |
| US-6734208-B2 | ADJUSTMENT TRANSFORMING GROWTH FACTOR CONCENTRATION; ANTIINFLAMMATORY AGENTS | NEORX CORPORATION | 2004-05-11 | — | — | US | disclosed |
| US-20030064970-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | NEORX CORPORATION | 2003-04-03 | — | — | US | disclosed |
| US-6410587-B1 | FIBROSIS; ALZHEIMER'S DISEASE; ANTIARTHRITIC AGENTS | NEORX CORPORATION | 2002-06-25 | — | — | US | disclosed |
| US-6117911-A | ADMINISTRATION OF AT LEAST ONE THERAPEUTIC AGENT THAT ELEVATES THE LEVEL OF TGF-BETA IN SAID MAMMAL. | NEORX CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
| WO-1998046588-A2 | COMPOUNDS AND THERAPIES FOR THE PREVENTION OF VASCULAR AND NON-VASCULAR PATHOLOGIES | NEORX CORPORATION (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084696-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | TGFB1, TGFB2, TEK | KDM4E 3256/4885EPHX2 710/4885CNR2 1099/4885 |
| US-20050020667-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | TGFB1, TGFB2, TEK | KDM4E 3256/4885EPHX2 710/4885CNR2 1099/4885 |
| US-20030064970-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | TGFB1, TGFB2, TEK | KDM4E 3256/4885EPHX2 710/4885CNR2 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.